Clinical Trials Logo

Dermatitis, Seborrheic clinical trials

View clinical trials related to Dermatitis, Seborrheic.

Filter by:

NCT ID: NCT00862654 Completed - Clinical trials for Scalp Seborrheic Dermatitis

Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis

Escape
Start date: March 2009
Phase: Phase 3
Study type: Interventional

The objective is to assess different treatment regimens with Clobetasol propionate shampoo 0.05% in the treatment of scalp Seborrheic Dermatitis.

NCT ID: NCT00830908 Completed - Clinical trials for Seborrheic Dermatitis

HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis

Start date: January 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether the stimulation of vascularization and cellular metabolism on the scalp by use of the HairMax LaserComb will produce improvement in the condition of scalp seborrheic dermatitis.

NCT ID: NCT00703846 Completed - Clinical trials for Dermatitis, Seborrheic

STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%

Start date: June 2008
Phase: Phase 4
Study type: Interventional

Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older. The approved dosing regimen is twice daily for 4 weeks. The treatment of recurrent seborrheic dermatitis demands a topical preparation that is safe for both short-term and chronic application. This study is being conducted in order to obtain long-term safety data on the use of Extina (ketoconazole) Foam, 2% in the treatment of seborrheic dermatitis.

NCT ID: NCT00565279 Completed - Clinical trials for Seborrheic Dermatitis

Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis

Start date: December 2007
Phase: Phase 3
Study type: Interventional

A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. This study will test the efficacy and safety of ASF1057 in the treatment of patients with seborrhoeic dermatitis.

NCT ID: NCT00408330 Completed - Clinical trials for Seborrheic Dermatitis on the Face

A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.

NCT ID: NCT00403559 Completed - Clinical trials for Seborrheic Dermatitis

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

Start date: May 7, 2007
Phase: Phase 2
Study type: Interventional

This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis